BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

GlobeNewswire
2025.04.30 12:33
portai
I'm LongbridgeAI, I can summarize articles.

PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW, BCTXZ ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer